The evolution of drug discovery: from phenotypes to targets, and back
Author:
- 30 March 2016
- journal article
- review article
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (5) , 788-798
Abstract
Cumulative scientific and technological advances over the past two centuries have transformed drug discovery from a largely serendipitous process into the high tech pipelines of today.Keywords
Funding Information
- National Institutes of Health (HD057632)
This publication has 123 references indexed in Scilit:
- Using transcriptome sequencing to identify mechanisms of drug action and resistanceNature Chemical Biology, 2012
- Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)Drug Discovery Today: Disease Mechanisms, 2011
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Targeting the cancer kinome through polypharmacologyNature Reviews Cancer, 2010
- High-content screening of primary neurons: ready for prime timeCurrent Opinion in Neurobiology, 2009
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chemical Biology, 2008
- Recognizing and exploiting differences between RNAi and small-molecule inhibitorsNature Chemical Biology, 2007
- Reconstitution of Modular PDK1 Functions on Trans-Splicing of the Regulatory PH and Catalytic Kinase DomainsBioconjugate Chemistry, 2007
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004
- Drug target validation and identification of secondary drug target effects using DNA microarraysNature Medicine, 1998